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of Non-Puerto Rican Hermansky–Pudlak Syndrome
Patients of Hispanic Descent
Carmelo Carmona-Rivera1, Gretchen Golas2, Richard A. Hess1, Nicholas D. Cardillo1, Elijah H. Martin1,
Kevin O’Brien2, Ekaterini Tsilou3, Bernadette R. Gochuico1, James G. White4, Marjan Huizing1
and William A. Gahl1,2
Hermansky–Pudlak syndrome (HPS) is an autosomal recessive condition characterized by a bleeding diathesis
and hypopigmentation of the skin, hair, and eyes. Some HPS patients develop other complications such as
granulomatous colitis and/or fatal pulmonary fibrosis. Eight genes have been associated with this condition,
resulting in subtypes HPS-1 through HPS-8. The HPS gene products are involved in the biogenesis of specialized
lysosome-related organelles such as melanosomes and platelet delta granules. HPS1 and HPS4 form a
stable complex named biogenesis of lysosome-related organelles complex (BLOC)-3, and patients with BLOC-3
or AP-3 deficiency develop pulmonary fibrosis. Therefore, it is important to subtype each HPS patient. HPS type 1
(HPS-1) occurs frequently on the island of Puerto Rico because of a founder mutation. Here, we describe
seven mutations, six of which, to our knowledge, are previously unreported in the HPS1, HPS4, and HPS5 genes
among patients of Mexican, Uruguayan, Honduran, Cuban, Venezuelan, and Salvadoran ancestries. Our
findings demonstrate that the diagnosis of HPS should be considered in Hispanic patients with oculocutaneous
albinism and bleeding symptoms. Moreover, such patients should not be assumed to have the HPS-1 subtype
typical of northwest Puerto Rican patients. We recommend molecular HPS subtyping in such cases, as it may
have significant implications for prognosis and intervention.
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INTRODUCTION
The Hermansky–Pudlak syndrome (HPS; OMIM 203300) is a
rare multisystemic disorder characterized by oculocutaneous
albinism and a bleeding diathesis, sometimes accompanied
by immunodeficiency, granulomatous colitis, and/or fatal
pulmonary fibrosis (Hermansky and Pudlak, 1959; Schinella
et al., 1980; Gahl et al., 1998; Brantly et al., 2000). These
clinical manifestations are due to defects in the formation
or function of lysosome-related organelles such as melano-
somes in melanocytes, platelet delta granules, lung lamellar
bodies, and/or lytic granules of cytotoxic T cells (Wei, 2006;
Huizing et al., 2008). HPS is caused by defects in one of eight
genes: HPS1, AP3B1, and HPS3 to HPS8 (Oh et al., 1996;
Dell’Angelica et al., 1999; Anikster et al., 2001; Suzuki et al.,
2002; Li et al., 2003; Zhang et al., 2003; Morgan et al., 2006).
With the exception of the gene encoding a subunit of AP-3
(HPS-2; Dell’Angelica et al., 1999), the HPS genes encode
new proteins of unknown function that have no homology to
any other protein and no recognizable motif. In addition, HPS
gene products have been identified as subunits of at least three
multiprotein complexes, named Biogenesis of Lysosome-
related Organelles Complex (BLOC)-1 to -3. BLOC-1 is a
multimeric complex composed of HPS7 and HPS8, among
other subunits (Li et al., 2003; Starcevic and Dell’Angelica,
2004; Morgan et al., 2006). BLOC-2 is composed of HPS3,
HPS5, and HPS6 (Di Pietro et al., 2004), whereas HPS1 and
HPS4 are subunits of BLOC-3 (Martina et al., 2003; Nazarian
et al., 2003). Deficiency of any of these complexes can affect
intracellular trafficking of proteins (Dell’Angelica, 2004).
Patients who have mutations in the same BLOC exhibit
similar phenotypes (Wei, 2006; Huizing et al., 2008). BLOC-3-
deficient patients exhibit a relatively more severe phenotype
of hypopigmentation, frequently develop granulomatous
colitis, and suffer a fatal, adult-onset pulmonary fibrosis
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(Hermos et al., 2002; Anderson et al., 2003; Huizing et al.,
2008). Patients with deficiency in BLOC-2 manifest a milder
phenotype of variable hypopigmentation and sporadic
granulomatous colitis, but pulmonary fibrosis has not been
found in BLOC-2 patients (Huizing et al., 2001, 2004, 2009).
So far, only two BLOC-1 patients have been reported, one
HPS-7 patient (Li et al., 2003) and one HPS-8 family (Morgan
et al., 2006); however, no detailed clinical features have been
provided apart from hypopigmentation, silvery hair (in HPS-
8), and a bleeding diathesis.
HPS has been described in patients worldwide (Witkop
et al., 1990; Brantly et al., 2000; Huizing et al., 2001;
Anderson et al., 2003; Ito et al., 2005; Merideth et al., 2009;
Vincent et al., 2009) but is common on the island of Puerto
Rico. One in 1,800 Puerto Ricans in the northwest part of the
island suffers from HPS type 1 (HPS-1; Witkop et al., 1990)
because of a 16 bp duplication in exon 15 of the HPS1 gene
(Oh et al., 1996). In central Puerto Rico, one in 4,000 natives
has HPS-3 because of another founder mutation, a 3,904-bp
deletion in the HPS3 gene (Anikster et al., 2001; Santiago
Borrero et al., 2006).
Here we report six non-Puerto Rican Hispanic HPS patients.
All of these individuals presented with pale to light skin color,
nystagmus, and bleeding problems including epistaxis and
easy bruising. Molecular analysis revealed that none of these
patients carried the Puerto Rican 16 bp deletion in HPS1, nor
the 3,904 bp deletion in HPS3 founder mutations, but instead
had other mutations in the HPS1, HPS4, and HPS5 genes.
These cases emphasize the molecular variability of HPS
among non-Puerto Rican, Hispanic HPS patients.
RESULTS AND DISCUSSION
Clinical findings
Patient HPS117-1 was a 29-year-old Mexican man who
was treated for advanced pulmonary fibrosis and symptoms
of inflammatory bowel disease. The diagnosis of HPS
was suspected because he had albinism, nystagmus, and
pulmonary fibrosis on computed tomography scan and
lung biopsy. On electron microscopic examination, the
platelets showed no dense bodies (Figure 2a). The patient
was referred to the National Institutes of Health, where DNA
analysis revealed a heterozygous mutation in exon 11 of
HPS1, i.e., c.972delC; p. M325WfsX6 (Figure 1a and
Supplementary Figure S1a online). The patient reported
relatively severe exertional dyspnea, fatigue, and a progres-
sive cough present for more than a year. Pulmonary function
tests revealed severe restriction and a severe reduction in gas
exchange; the forced vital capacity was 44% of predicted,
total lung capacity was 52% of predicted, and diffusion
capacity for carbon monoxide was 43% of predicted.
Conventional and high-resolution chest computerized axial
tomography scans showed diffuse bilateral interstitial infil-
trates (Figure 2b). Biopsies from a colonoscopy revealed
evidence of colitis in the sigmoid colon and rectum. The
patient died from complications of end-stage pulmonary
fibrosis at age 30.
Patient HPS118-1, the sister of HPS117-1, is a 39-year-old






































































































Figure 1. Clinical and molecular findings among non-Puerto Rican Hispanic
Hermansky–Pudlak syndrome (HPS) patients. (a) Pigmentation and
sequencing chromatograms of all six patients reported in this study. All
patients showed hypopigmented skin with hair colors ranging from blond to
brown. (b) Representative images of iris transillumination (in HPS117-1) and
pale fundus (in HPS118-1), compared with controls (Ctrl).
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hypertension, and rheumatoid arthritis. She has three
unaffected siblings, but her paternal great grandfather
reportedly had albinism. Her initial National Institutes of
Health evaluation at age 32 revealed that she had a
heterozygous mutation in HPS1: c.972delC; p. M325WfsX6
(exon 11; Figure 1a); platelet electron microscopy confirmed
the absence of dense bodies. She had no symptoms of lung
disease, but a computed tomography scan showed mild
bilateral basilar peripheral interstitial lung opacities (Figure
2b). Pulmonary function testing showed mild restriction with
a total lung capacity of 70% of predicted and a mild
reduction in diffusion capacity. At age 33, she was diagnosed
with rheumatoid arthritis and essential hypertension, both of
which are well controlled with medications.
Her recent evaluation at age 39 revealed some progression
of her lung disease, but she remains asymptomatic. High-
resolution chest computerized axial tomography showed a
mild increase in fibrosis in the lung bases, especially on the
right, and continued involvement in the right middle lobe.
Pulmonary function test results were stable, with an forced
vital capacity 69% of predicted, total lung capacity 70% of
predicted, and an adjusted diffusion capacity for carbon
monoxide 64% of predicted.
Patient HPS125-5 is an 8-month-old boy of Mexican
ancestry with brown hair (Figure 1a) and irides, decreased
retinal pigmentation, and nystagmus. He had easy bruising
(Supplementary Figure S1c online) and epistaxis, which led to
the discovery of absent platelet dense bodies (Supplementary
Figure S1c online). He has no signs of colitis. DNA analysis
showed a heterozygous mutation in HPS5: c.1423delC;
p.L475SfsX37 (exon 12; Figure 1a).
Patient HPS150-4 is a 2-year-old boy of Uruguayan ancestry
with HPS-4. He has blond hair, gray irides (Figure 1a), iris
transillumination, nystagmus, and pale fundi. He presented
with easy bruising (Supplementary Figure S1c online). Bloody
stools began at 18 months, along with epistaxis and prolonged
gingival bleeding after trauma. His platelets showed no dense
bodies. Genomic DNA revealed two compound heterozygous
mutations in HPS4: c.45 G4A; p.W15X (exon 3) and
c.47delA; p.N16IfsX11 (exon3; Figure 1a).
Patient HPS163-1 is a 16-year-old boy of Honduran-
Salvadoran ancestry. He has pale skin and his blond hair has
darkened considerably since birth (Figure 1a); his irides are
brown (Figure 1a) and nystagmus is present. Bruising was








Figure 2. Hallmarks of Hermansky–Pudlak syndrome (HPS) patients.
(a) Representative whole-mount (top panel) and transmission (bottom panel)
electron microscope images of selected patients compared with controls
(Ctrl), showing an absence of platelet delta granules (arrows in control
images). (b) Conventional chest computed tomography (CT) of HPS117-1 (top
image) shows diffuse bilateral peripheral interstitial pulmonary infiltrates
(arrows). A CT scan from HPS118-1 (middle image) shows mild bilateral
interstitial opacities (arrows) predominantly in subpleural areas. In contrast,
no pulmonary infiltrates were found on a CT scan from HPS361-1 (bottom
image), who is a 22-year-old man with HPS-1 and no lung disease.
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of abdominal pain, bloody diarrhea, and anal fissures
prompted treatment for Crohn’s disease. Nausea caused a
20-pound weight loss; syncopal episodes and anemia led
to a colectomy with end ileostomy. Repair of a perfora-
ted bowel required 18 U of platelets. There were no
pulmonary symptoms. DNA analysis showed a homozy-
gous mutation in HPS1, i.e., c.467_476del; p.Y156CfsX16
(exon 6; Figure 1a).
Patient HPS353-5 is a 3 and 9/12-year-old boy of
Cuban-Venezuelan ancestry. He has medium brown hair,
brown irides (Figure 1a), and nystagmus with photosensi-
tivity. Ocular albinism was considered, but genetic testing
for X-linked ocular albinism was negative. Although there
was no excessive bleeding during previous surgeries (i.e.,
circumcision, strabismus, or dental surgery), the patient
presented with easy bruising (Supplementary Figure S1c
online) of his lower extremities and two minor episodes of
spontaneous epistaxis. On electron microscopic examina-
tion, his platelets showed no dense bodies (Supplementary
Figure S1b online). He had no manifestations of colitis. His
visual acuity was OD 20/100 and OS 20/125 with pendular
horizontal nystagmus, diffuse iris transillumination, optic
disc pallor, and blond periphery of the retinae with no foveal
reflex. DNA analysis revealed compound heterozygous
mutations in HPS5, i.e., c.302_305delTTTG; p.V101GfsX3
(exon 5) and c.1,634þ1G4A (intron 13; Figure 1a).
Molecular and cellular analysis
DNA sequencing of all coding exons and intronic boundaries
of the HPS1, HPS3, HPS4, HPS5, and HPS6 genes (Wei,
2006; Huizing et al., 2008) revealed the mutations listed in
Table 1.
In addition, the patients’ fibroblast proteins were electro-
phoresed and immunoblotted using antibodies against HPS4
to evaluate the protein expression of BLOC-3, consisting of
HPS1 and HPS4, and against HPS5 to evaluate BLOC-2,
consisting of HPS3, HPS5, and HPS6 (Figure 3). Mutation in
one member of a BLOC complex destabilizes the entire
complex, causing degradation of the other proteins in the


















































Figure 3. Immunoblot analysis of patients’ fibroblast extracts.
Immunoblotting was performed with antibodies against Hermansky–Pudlak
syndrome (HPS)4 (to detect BLOC-3 defects), HPS5 (to detect BLOC-2
defects), and a-tubulin (loading control). (a) Normal, HPS-3, and HPS-1
fibroblast extracts were loaded as controls (lanes 1–3) and compared with the
patients’ protein expression. Patient HPS117-1 showed decreased HPS4
expression, similar to that of control HPS-1 cells (lane 3), suggesting an HPS-1
defect. Patients HPS125-5 and HPS353-5 expressed no HPS5 protein,
confirming an HPS-5 defect. Patient HPS150-4 expressed no HPS4 protein,
confirming an HPS-4 defect. (b) Patient HPS163-1 showed reduced levels of
HPS4 protein, similar to the HPS-1 loading control (lane 1), suggesting HPS-1
disease in this patient.
Table 1. Summary of clinical and molecular features in non-Puerto Rican Hispanic patients
Patient Age Sex Ancestry Gene Allele 1 Allele 2 Bleeding
Lung
fibrosis GI
HPS117-1 29 years M Mex HPS1 c.972delC (ex 11)
p.M325WfsX6
ND Br + (FVC 44%) 
HPS118-1 39 years F Mex HPS1 c.972delC (ex 11)
p.M325WfsX6
ND Br + (FVC 69%) 
HPS125-5 8 months M Mex HPS5 c.1423delC (ex 12)
p.L475SfsX37
ND E, Br  
HPS150-4 2 years M Uru HPS4 c.45G4A (ex 3)
p.W15X
c.47delA p.N16IfsX11 E, Br  





HPS353-5 3 years M Cub/Ven HPS5 c.302_305delTTTG
p.V101GfsX3 (ex 5)
c.1,634+1G4A (in 13) E, Br  
Abbreviations: +, present; , absent; Br, easy bruising; Cub, Cuban; E, epistaxis; F, female; FVC, forced vital capacity; GI, gastrointestinal symptoms;
Hon, Honduran; M, male; ND, not determined; Mex, Mexican; Sal, Salvadoran; Uru, Uruguayan; Ven, Venezuelan.
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member of BLOC-3 (HPS4) or BLOC-2 (HPS5) assists in
demonstrating the deficiency of other members of the same
complex (Nazarian et al., 2008).
These immunoblotting techniques also demonstrated the
pathogenicity of certain mutations in cases where we found
only one mutation in an HPS gene. For example, HPS117-1
and HPS118-1 carried a single copy of c.972delC in HPS1.
This frame-shift mutation generates a premature termination
codon and causes nonsense-mediated RNA decay (Shoteler-
suk et al., 1998). It was previously found in Puerto Rican
patients (Carmona-Rivera et al., 2010), but has also been
described in other Caucasians (Oh et al., 1998) and in
an African-American (Merideth et al., 2009). In fact, the
C-nucleotide at position 972 was recognized as an HPS1
mutation ‘‘hotspot’’ (Oh et al., 1998). However, no second
mutation could be found in our patient’s coding region of
HPS1; therefore, we used immunoblotting of HPS117-1
fibroblast extracts to illustrate a dramatic reduction in the
levels of the HPS4 antibody signal, similar to that of HPS-1
control fibroblast extracts. This suggested a lack of functional
HPS1 (Figure 3a); the patients’ second HPS1 mutation
probably involves a non-coding region of HPS1.
DNA analysis of patient HPS125-5 showed a previously
unreported single-copy mutation in HPS5, c.1423delC
(Figure 1a), causing a frame shift and generating a premature
termination codon. No second mutation was found, but
protein analysis showed a complete absence of HPS5 protein
in this patient’s fibroblasts (Figure 3a), supporting the
diagnosis of HPS-5.
Sequence analysis of HPS150-4 showed two unreported
compound heterozygous mutations in exon 3 of the HPS4
gene, a nonsense mutation and a 1-bp deletion leading to
a premature termination codon (Figure 1a). RNA trans-
cripts from both alleles are likely to be degraded by
nonsense-mediated RNA decay, a prediction supported by
complete absence of the HPS4 protein in the patient’s
fibroblasts (Figure 3a).
Similarly, an unreported homozygous 10-bp deletion in
exon 6 of HPS1, found in HPS163-1 (Figure 1a), is predicted
to result in nonsense-mediated RNA decay. We used
quantitative PCR (Griffin et al., 2005) to rule out hemi-
zygosity in this patient; quantitative PCR demonstrated the
presence of two HPS1 alleles, confirming homozygosity of
the 10-bp deletion (data not shown). In addition, protein
expression levels of HPS4 were reduced (Figure 3b),
suggesting degradation of HPS4 in the absence of the
HPS1 protein.
Patient HPS353-5 was compound heterozygous for
two unreported mutations in HPS5, including a 4-bp deletion
(TTTG) in exon 5 leading to a premature termination codon.
The second mutation was a splice-site variant in intron 13
(c.1,634þ 1G4A). To demonstrate aberration in splicing, we
amplified HPS5 complementary DNA using primers located
in exon 11 and exon 16 (Figure 4a). In addition to the
expected 694-bp PCR product, we found a band ofB570 bp
(Figure 4b). Sequence analysis of the additional band
demonstrated skipping of exon 13 (124-bp; Figure 4c),
altering the reading frame. Immunoblot analysis showed total
absence of the HPS5 protein in fibroblasts of patient HPS353-
5 compared with normal (Figure 3a), indicating that these two
mutations have pathogenic implications for the HPS5 gene
product.
In summary, we report six non-Puerto Rican Hispanic
HPS patients with Mexican, Uruguayan, Honduran, Cuban,
Venezuelan, and Salvadoran ancestries, identifying mutations
in the HPS1, HPS4, and HPS5 genes (Table 1). Importantly,
we did not identify the two common Puerto Rican HPS
founder mutations, i.e., the 16-bp duplication in HPS1 and
the 3,904-bp deletion in HPS3, in our cohort. Hispanic
patients with oculocutaneous albinism and bleeding symp-
toms should not be assumed to have the HPS-1 subtype
typical of northwest Puerto Rican patients. We recommend
molecular HPS subtyping in such cases, as a diagnosis of
the type of HPS allows anticipation of clinical complica-
tions, appropriate management, and genetic counseling
(Gahl et al., 2002; Huizing et al., 2008).
MATERIALS AND METHODS
Patients and cells
All patients in this study were enrolled in the clinical proto-
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Figure 4. Complementary DNA (cDNA) analysis of patient HPS353-5.
(a) Schematic representation of the HPS5 gene and location of the primers
used for PCR analysis to detect splice-site alteration in patient HPS353-5.
The patient’s splice-site variant c.1,634þ 1G4A (intron 13) is located 1-bp
intronic from the exon12–exon13 boundary (asterisk). (b) cDNA amplification
of exons 11–16 of the HPS5 cDNA transcript showing the expected band of
694 bp and a lower-molecular-weight band around 570 bp. (c) Sequence
analysis of the lower-molecular-weight band revealed skipping of exon 13
(124-bp) in patient HPS353-5, confirming the pathogenicity of the new HPS5
splice-site variant in this patient.
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Syndrome’’ (NCT00001456, www.clinicaltrials.gov), approved by
the NHGRI (National Human Genome Research Institute) Institu-
tional Review Board and adhered to Declaration of Helsinki
Principles. All patients or their parents provided written, informed
consent. Patients were diagnosed with HPS on the basis of the
presence of oculocutaneous albinism (i.e., decreased visual acuity,
nystagmus, and some degree of hypopigmentation relative to family
members) and the absence of platelet delta granules on whole-
mount electron microscopy.
Primary cultures of skin fibroblasts, obtained from a 4-mm
punch biopsy, were grown in DMEM supplemented with 10% fetal
bovine serum containing 100 U ml1 penicillin and 0.1 mg ml1
streptomycin.
Electron microscopy of platelet delta granules
Presence of platelet delta granules in platelet-rich plasma was
analyzed using whole-mount and transmission electron microscopy
as previously described (Witkop et al., 1987; Huizing et al., 2007).
Molecular analysis
Genomic DNA was isolated from patients’ peripheral blood mono-
nuclear cells using the Gentra Puregene Blood Kit (Qiagen,
Valencia, CA). All HPS1, HPS3, HPS4, HPS5, and HPS6 coding
exons and flanking intronic boundaries were amplified by PCR
amplification and subjected to bi-directional sequencing. RNA
was extracted from fibroblasts using the RNeasy Mini kit (Qiagen)
and transcribed into complementary DNA using the SuperScript III
First-Strand Synthesis System for RT-PCR (Invitrogen, Carlsbad, CA).
Primer sequences for amplifying exons 11–16 of HPS5 (Figure 3)
were as follows: forward 50-GACTGCAGATAAATTGGAGCATTT-30
and reverse 50-GTAGCTTGGTCATTGCTTCTGCTG-30.
Sequencing was performed using ABI BigDye Terminator
chemistry (Applied Biosystems, Foster City, CA) with detection on
an ABI 3130x1 genetic analyzer (Applied Biosystems). Results were
analyzed using Sequencher v4.9 software (Gene Codes Corporation,
Ann Arbor, MI).
Pulmonary function testing and lung computed tomography
scanning
Pulmonary function testing measurements were taken using
standard equipment according to American Thoracic Society
recommendations as previously described (SensorMedics, Yorba
Linda, CA; Rouhani et al., 2009). Conventional and high-resolution
computed tomography scans of the chest were performed as
previously described, without intravenous contrast during end-
inspiration in the supine and prone positions, respectively (General
Electric Medical Systems, Milwaukee, WI; Gochuico et al., 2008).
Immunoblotting
Fibroblast pellets were lysed by incubation in ice-cold lysis buffer
(50 mM Tris-HCl pH 7.4, 300 mM NaCl, 0.5% w/v Triton X-100,
5 mM EDTA, 1 protease inhibitor cocktail (Roche Applied Science,
Indianapolis, IN)) for 30 minutes at 4 1C, followed by centrifugation
at 16,000 g for 15 minutes. Protein concentrations were deter-
mined using the BCA Protein Assay (Pierce, Rockford, IL). Total
protein samples (20 mg) were separated on a 4–12% gradient
NuPAGE Bis-Tris Gel (Invitrogen) and blotted to nitrocellulose
membranes. Membranes were blocked with 10% BSA for 30 minutes
at room temperature, followed by incubation with one of three
primary antibodies, namely, rabbit polyclonal antibodies against
HPS4 (1:500; H-150; Santa Cruz Biotechnology, Santa Cruz, CA),
rabbit polyclonal antibody against HPS5 (1:500; Proteintech Group,
Chicago, IL), or mouse mAb against a-tubulin (1:10,000; Sigma,
St Louis, MO). Subsequently, the membranes were probed with
either secondary donkey anti-rabbit or anti-mouse antibodies,
horseradish peroxidase linked (1:10,000; GE Healthcare, UK),
followed by detection with enhanced chemiluminescence western
blotting substrate from Pierce (Rockford, IL), or with secondary
IRDye 800CW goat anti-rabbit or anti-mouse antibodies (1:10,000)
for 1 hour at room temperature and detected using the Li-Cor
Odyssey Infrared Imaging System as per the manufacturer’s instruc-
tions (Li-Cor Biosciences, Lincoln, NE).
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